度伐利尤单抗用于尿路上皮癌的治疗：关于新出现的数据和治疗潜力的简短综述

Baldini Capucine, Champiat Stéphane, Vuagnat Perrine, Massard Christophe

Drug Development Department, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France,

Onco Targets Ther. 2019 Apr 3;12:2505-2512. doi: 10.2147/OTT.S141040. eCollection 2019.

Urothelial carcinoma (UC) is the second most frequent urogenital malignancy with high incidence in the United States and Europe. Despite poor prognosis, new treatments have emerged with great efficacy and safety such as immune checkpoint inhibitors. Durvalumab, an anti Programmed Death Ligand 1, has been given breakthrough in UC in 2017 in patients who have disease progression during or following platinum-containing chemotherapy or who have disease progression <12 months after neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. Food and Drug Administration approval was given on the results of the Phase I/II study of MEDI 4736. In this article, we will review available data on durvalumab in the treatment of locally advanced and metastatic UC and discuss therapeutic potential.

尿路上皮癌（UC）是第二常见的泌尿生殖系统恶性肿瘤，在美国和欧洲发病率较高。尽管预后较差，但免疫检查点抑制剂等新疗法已出现，具有很高的疗效和安全性。度伐利尤单抗是一种抗程序性死亡配体1药物，于2017年在UC治疗方面取得突破，适用于在含铂化疗期间或之后出现疾病进展的患者，或在含铂化疗新辅助或辅助治疗后<12个月出现疾病进展的患者。美国食品药品监督管理局根据MEDI 4736的I/II期研究结果给予了批准。在本文中，我们将回顾度伐利尤单抗治疗局部晚期和转移性UC的现有数据，并讨论其治疗潜力。